These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31253998)

  • 1. Reduced CTL motility and activity in avascular tumor areas.
    Manaster Y; Shipony Z; Hutzler A; Kolesnikov M; Avivi C; Shalmon B; Barshack I; Besser MJ; Feferman T; Shakhar G
    Cancer Immunol Immunother; 2019 Aug; 68(8):1287-1301. PubMed ID: 31253998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
    Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
    Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Culturing CTLs under Hypoxic Conditions Enhances Their Cytolysis and Improves Their Anti-tumor Function.
    Gropper Y; Feferman T; Shalit T; Salame TM; Porat Z; Shakhar G
    Cell Rep; 2017 Sep; 20(11):2547-2555. PubMed ID: 28903036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor.
    Boissonnas A; Fetler L; Zeelenberg IS; Hugues S; Amigorena S
    J Exp Med; 2007 Feb; 204(2):345-56. PubMed ID: 17261634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.
    Goding SR; Yu S; Bailey LM; Lotze MT; Basse PH
    Clin Immunol; 2017 Apr; 177():76-86. PubMed ID: 27377534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell distribution and adhesion receptor expression in metastatic melanoma.
    Weishaupt C; Munoz KN; Buzney E; Kupper TS; Fuhlbrigge RC
    Clin Cancer Res; 2007 May; 13(9):2549-56. PubMed ID: 17473183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.
    Oflazoglu E; Elliott M; Takita H; Ferrone S; Henderson RA; Repasky EA
    J Transl Med; 2007 Jun; 5():29. PubMed ID: 17592641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
    Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
    Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.
    Carretero R; Sektioglu IM; Garbi N; Salgado OC; Beckhove P; Hämmerling GJ
    Nat Immunol; 2015 Jun; 16(6):609-17. PubMed ID: 25915731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.
    Jazirehi AR; Baritaki S; Koya RC; Bonavida B; Economou JS
    Cancer Res; 2011 Feb; 71(4):1406-17. PubMed ID: 21159666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
    Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
    J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Analysis of Immune Infiltrates in Primary Melanoma.
    Gartrell RD; Marks DK; Hart TD; Li G; Davari DR; Wu A; Blake Z; Lu Y; Askin KN; Monod A; Esancy CL; Stack EC; Jia DT; Armenta PM; Fu Y; Izaki D; Taback B; Rabadan R; Kaufman HL; Drake CG; Horst BA; Saenger YM
    Cancer Immunol Res; 2018 Apr; 6(4):481-493. PubMed ID: 29467127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
    Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
    J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression.
    Yang D; Ud Din N; Browning DD; Abrams SI; Liu K
    Clin Cancer Res; 2007 Sep; 13(17):5202-10. PubMed ID: 17785576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.